{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T17:20:08Z","timestamp":1761844808445,"version":"build-2065373602"},"reference-count":36,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immunobiology"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.imbio.2017.10.021","type":"journal-article","created":{"date-parts":[[2017,10,11]],"date-time":"2017-10-11T13:15:30Z","timestamp":1507727730000},"page":"1-7","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Sub-optimal primary surgery leads to unfavorable immunological changes in ovarian cancer patients"],"prefix":"10.1016","volume":"223","author":[{"given":"Marek","family":"Nowak","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ewa","family":"G\u0142owacka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Przemys\u0142aw","family":"Lewkowicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ma\u0142gorzata","family":"Banasik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krzysztof","family":"Szy\u0142\u0142o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kinga","family":"Zimna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katarzyna","family":"Bednarska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magdalena","family":"Klink","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.imbio.2017.10.021_bib0005","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.rinim.2012.10.003","article-title":"Circulating interleukin-8 and plasminogen activator inhibitor-1 are increased in women with ovarian carcinoma","volume":"2","author":"Aune","year":"2012","journal-title":"Results Immunol."},{"key":"10.1016\/j.imbio.2017.10.021_bib0010","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0020-7292(00)90001-8","article-title":"FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology","volume":"70","author":"Benedet","year":"2000","journal-title":"Int. J. Gynaecol. Obstet."},{"key":"10.1016\/j.imbio.2017.10.021_bib0015","first-page":"635","article-title":"Ovarian cancer: diagnosis and treatment","volume":"108","author":"Burges","year":"2011","journal-title":"Dtsch \u00c4rztebl Int"},{"key":"10.1016\/j.imbio.2017.10.021_bib0020","first-page":"667","article-title":"Signaling defects and functional impairment in T-cells from cervical cancer patients","volume":"24","author":"Cheriyan","year":"2009","journal-title":"Cancer Biother. Radiopharm."},{"key":"10.1016\/j.imbio.2017.10.021_bib0025","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/S0885-3924(00)00199-8","article-title":"Cytokines and advanced cancer","volume":"20","author":"Dunlop","year":"2000","journal-title":"J. Pain Symptom Manage."},{"key":"10.1016\/j.imbio.2017.10.021_bib0030","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.smim.2014.01.008","article-title":"The two faces of IL-6 in the tumor microenvironment","volume":"26","author":"Fisher","year":"2014","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.imbio.2017.10.021_bib0035","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1089\/10799900252952262","article-title":"Circulating levels of interleukin-10 and interleukin-6 in gastric and colon cancer patients before and after surgery: relationship with radicality and outcome","volume":"22","author":"Galizia","year":"2002","journal-title":"J. Interferon Cytokine Res."},{"key":"10.1016\/j.imbio.2017.10.021_bib0040","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s10555-006-9006-2","article-title":"Transforming growth factor-beta in cancer and metastasis","volume":"25","author":"Jakowlew","year":"2006","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.imbio.2017.10.021_bib0045","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.clinbiochem.2004.01.014","article-title":"Vascular endothelial growth factor and interleukin-8 are associated with poor prognosis in epithelial ovarian cancer patients","volume":"37","author":"Kassim","year":"2004","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.imbio.2017.10.021_bib0050","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1186\/1479-5876-11-147","article-title":"Immunity of human epithelial ovarian carcinoma the paradigm of immune suppression in cancer","volume":"11","author":"Lavou\u00e9","year":"2013","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.imbio.2017.10.021_bib0055","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1158\/1078-0432.CCR-08-2966","article-title":"Surgical stress promotes tumor growth in ovarian carcinoma","volume":"15","author":"Lee","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.imbio.2017.10.021_bib0060","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.canlet.2007.01.024","article-title":"Human ovarian carcinoma cells generate CD4(+)CD25(+) regulatory T cells from peripheral CD4(+)CD25 (\u2212) T cells through secreting TGF-beta","volume":"253","author":"Li","year":"2007","journal-title":"Cancer Lett."},{"key":"10.1016\/j.imbio.2017.10.021_bib0065","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1067\/msy.2000.101584","article-title":"Inflammatory cytokines and cell response in surgery","volume":"127","author":"Lin","year":"2000","journal-title":"Surgery"},{"key":"10.1016\/j.imbio.2017.10.021_bib0070","doi-asserted-by":"crossref","first-page":"247","DOI":"10.20452\/pamw.144","article-title":"Clinical significance of interleukin-6 (IL-6) as a prognostic factor of cancer disease","volume":"117","author":"\u0141ukaszewicz","year":"2007","journal-title":"Pol Arch Med Wewn\u0119trznej"},{"key":"10.1016\/j.imbio.2017.10.021_bib0075","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s00423-004-0472-0","article-title":"Surgical trauma: hyperinflammation versus immunosuppression?","volume":"389","author":"Menger","year":"2004","journal-title":"Langenbecks Arch. Surg."},{"key":"10.1016\/j.imbio.2017.10.021_bib0080","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1189\/jlb.0705358","article-title":"Interleukin-10 and the immune response against cancer: a counterpoint","volume":"78","author":"Mocellin","year":"2005","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.imbio.2017.10.021_bib0085","doi-asserted-by":"crossref","first-page":"937s","DOI":"10.1158\/1078-0432.937s.11.2","article-title":"Dual role of transforming growth factor beta in mammary tumorigenesis and metastatic progression","volume":"11","author":"Muraoka-Cook","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.imbio.2017.10.021_bib0090","first-page":"1715","article-title":"Expression of IL-10 in patients with ovarian carcinoma","volume":"26","author":"Mustea","year":"2006","journal-title":"Anticancer Res."},{"key":"10.1016\/j.imbio.2017.10.021_bib0095","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1111\/j.1582-4934.2009.00911.x","article-title":"Ovarian cancer cytoreduction induces changes in T cell population subsets reducing immunosuppression","volume":"14","author":"Napoletano","year":"2010","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.imbio.2017.10.021_bib0100","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1677\/erc.0.0060093","article-title":"The role of cytokines in both the normal and malignant ovary","volume":"6","author":"Nash","year":"1999","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.imbio.2017.10.021_bib0105","first-page":"375","article-title":"Proinflammatory and immunosuppressive serum, ascites and cyst fluid cytokines in patients with early and advanced ovarian cancer and benign ovarian tumors","volume":"31","author":"Nowak","year":"2010","journal-title":"Neuro Endocrinol. Lett."},{"key":"10.1016\/j.imbio.2017.10.021_bib0110","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1102\/1470-7330.2007.0030","article-title":"Cytoreductive surgery in ovarian cancer","volume":"7","author":"Pomel","year":"2007","journal-title":"Cancer Imaging"},{"key":"10.1016\/j.imbio.2017.10.021_bib0115","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.cytogfr.2010.11.001","article-title":"IL-10 family of cytokines","volume":"21","author":"Sabat","year":"2010","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.imbio.2017.10.021_bib0120","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1111\/j.1471-0528.2001.00206.x","article-title":"Increased levels of interleukin-10 and transforming growth factor-beta in the plasma and ascitic fluid of patients with advanced ovarian cancer","volume":"108","author":"Santin","year":"2001","journal-title":"BJOG Int. J. Obstet. Gynaecol."},{"key":"10.1016\/j.imbio.2017.10.021_bib0125","first-page":"111","article-title":"Surgical debulking of ovarian cancer: what difference does it make?","volume":"3","author":"Schorge","year":"2010","journal-title":"Rev. Obstet. Gynecol."},{"key":"10.1016\/j.imbio.2017.10.021_bib0130","first-page":"209","article-title":"In Pursuit of optimal cytoreduction in ovarian cancer patients: the role of surgery and surgeon","volume":"59","author":"Shashikant","year":"2009","journal-title":"J. Obstet. Gynecol. India"},{"key":"10.1016\/j.imbio.2017.10.021_bib0135","first-page":"366","article-title":"Clinical significance of serum transforming growth factor-beta 1 (TGF-\u03b21) levels in patients with epithelial ovarian cancer","volume":"35","author":"Tas","year":"2014","journal-title":"Tumour Biol."},{"key":"10.1016\/j.imbio.2017.10.021_bib0140","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/j.1365-2567.2006.02321.x","article-title":"Mechanisms of immune suppression by interleukin-10 and transforming growth factor-beta: the role of T regulatory cells","volume":"117","author":"Taylor","year":"2006","journal-title":"Immunology"},{"key":"10.1016\/j.imbio.2017.10.021_bib0145","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1006\/gyno.1997.4726","article-title":"Serum evaluation of interleukin 6 in ovarian cancer patients","volume":"66","author":"Tempfer","year":"1997","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.imbio.2017.10.021_bib0150","doi-asserted-by":"crossref","first-page":"6735","DOI":"10.1158\/1078-0432.CCR-07-4843","article-title":"The interleukin-8 pathway in cancer","volume":"14","author":"Waugh","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.imbio.2017.10.021_bib0155","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.semcancer.2005.07.008","article-title":"Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention","volume":"16","author":"Whiteside","year":"2006","journal-title":"Semin. Cancer Biol."},{"issue":"Suppl. 2","key":"10.1016\/j.imbio.2017.10.021_bib0160","doi-asserted-by":"crossref","first-page":"S272","DOI":"10.1016\/j.jaci.2009.09.045","article-title":"Immune responses to malignancies","volume":"125","author":"Whiteside","year":"2010","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.imbio.2017.10.021_bib0165","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1517\/14712598.2014.927432","article-title":"Induced regulatory T cells in inhibitory microenvironments created by cancer","volume":"14","author":"Whiteside","year":"2014","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.imbio.2017.10.021_bib0170","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1200\/JCO.2007.13.1953","article-title":"Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study","volume":"26","author":"Winter","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.imbio.2017.10.021_bib0175","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1359-6101(01)00016-8","article-title":"Interleukin-8 and human cancer biology","volume":"12","author":"Xie","year":"2001","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.imbio.2017.10.021_bib0180","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1177\/147323000703500302","article-title":"The expression of interleukin-10 in patients with primary ovarian epithelial carcinoma and in ovarian carcinoma cell lines","volume":"35","author":"Zhou","year":"2007","journal-title":"J. Int. Med. Res."}],"container-title":["Immunobiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0171298517301560?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0171298517301560?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T16:43:36Z","timestamp":1759250616000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0171298517301560"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["S0171298517301560"],"URL":"https:\/\/doi.org\/10.1016\/j.imbio.2017.10.021","relation":{},"ISSN":["0171-2985"],"issn-type":[{"type":"print","value":"0171-2985"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sub-optimal primary surgery leads to unfavorable immunological changes in ovarian cancer patients","name":"articletitle","label":"Article Title"},{"value":"Immunobiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.imbio.2017.10.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier GmbH. All rights reserved.","name":"copyright","label":"Copyright"}]}}